• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Avantor® Unifies Masterflex® Portfolio to Streamline Fluid Management from R&D to Bioprocess Manufacturing

    4/21/26 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVTR alert in real time by email

    Portfolio now includes standard, configurable, and engineered-to-order peristaltic pumps, single-use assemblies, and systems for R&D through high-volume manufacturing

    Company to attend INTERPHEX 2026 in New York City from April 21-23

    RADNOR, Pa., April 21, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to the life sciences and advanced technology industries, today announced the expansion of its Masterflex brand across its fluid handling portfolio, bringing together standard, configurable, and engineered-to-order peristaltic pumps, single-use assemblies, and systems.

    Masterflex fluid management portfolio including peristaltic pumps, tubing, mixers, assemblies, and engineered-to-order single-use systems for biopharma and bioprocessing applications

    "For decades, Masterflex has been synonymous with precision and reliability in peristaltic pumps used in fluid handling," said Benoit Gourdier, Executive Vice President, Bioscience & Medtech Products, Avantor. "Unifying our portfolio under the Masterflex name makes it easier for customers to tailor solutions, for their specific processes and molecules, within a consistent framework, supporting smoother transition from development to production."

    Designed for secure fluid transfer and reliable connections, Masterflex solutions support consistent performance as processes scale. The portfolio continues to advance bioprocessing applications, with PROFINET-enabled connectivity that supports interoperability between Masterflex peristaltic pumps and process control systems. New, purpose-built storage containers further support safe, efficient fluid handling and transfer across workflows. Combined with Avantor's J.T. Baker® high-purity process chemicals, these solutions provide a more unified bioprocessing approach.

    At INTERPHEX 2026

    Avantor will be attending INTERPHEX 2026, in New York City from April 21-23. The Company will demonstrate how this expansion enables biopharmaceutical customers to more easily select, configure, and deploy fluid handling solutions, reducing complexity and supporting more efficient scale-up.

    At Booth #3643, Avantor will showcase fully operational integrated fluid management systems, demonstrating controlled fluid transfer, seamless connectivity, and scalability from benchtop mixing through production-scale processing, including connected tangential flow filtration (TFF), storage, and pump solutions.

    INTERPHEX Technical Presentation

    Zeiny Aubdoollah, Scientist, R&D Applications at Avantor, will present how fluid handling technologies support performance from development through production and describe a study demonstrating the scalability of Avantor Magnetic Mixers. The presentation will take place on April 21, 1:00–1:30 PM EST in Tech Theater B inside the exhibit hall.

    Learn more about Avantor's fluid handling portfolio here.

    About Avantor

    Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit corporate.avantorsciences.com on LinkedIn, X (Twitter) and Facebook.

    Global Media Contact

    Eric Van Zanten

    Head of External Communications

    Avantor

    610-529-6219

    [email protected]

    Investor Relations Contact

    Chris Fidyk

    Vice President, Investor Relations

    Avantor

    [email protected]

    Masterflex stainless steel and collapsible bioprocessing containers designed for secure fluid handling in biopharma and bioprocessing applications

    PROFINET® network connectivity available on Masterflex® MasterSense® and ISMATEC® touchscreen peristaltic pumps for process control and system monitoring in fluid handling applications

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-unifies-masterflex-portfolio-to-streamline-fluid-management-from-rd-to-bioprocess-manufacturing-302747536.html

    SOURCE Avantor and Financial News

    Get the next $AVTR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVTR

    DatePrice TargetRatingAnalyst
    3/6/2026$8.50Equal Weight → Underweight
    Barclays
    1/5/2026$12.00Outperform → In-line
    Evercore ISI
    12/17/2025$9.00Hold → Underperform
    Jefferies
    12/15/2025$13.00Buy → Neutral
    BofA Securities
    11/4/2025Outperform → Mkt Perform
    Raymond James
    10/30/2025$12.00Overweight → Equal Weight
    Barclays
    10/30/2025$12.00Overweight → Neutral
    Analyst
    8/1/2025Buy → Hold
    Jefferies
    More analyst ratings

    $AVTR
    SEC Filings

    View All

    Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    4/1/26 8:06:37 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEFA14A filed by Avantor Inc.

    DEFA14A - Avantor, Inc. (0001722482) (Filer)

    3/27/26 7:43:46 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEF 14A filed by Avantor Inc.

    DEF 14A - Avantor, Inc. (0001722482) (Filer)

    3/27/26 7:40:51 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Avantor downgraded by Barclays with a new price target

    Barclays downgraded Avantor from Equal Weight to Underweight and set a new price target of $8.50

    3/6/26 8:24:43 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Avantor from Outperform to In-line and set a new price target of $12.00

    1/5/26 8:46:17 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Jefferies with a new price target

    Jefferies downgraded Avantor from Hold to Underperform and set a new price target of $9.00

    12/17/25 8:49:45 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avantor® Unifies Masterflex® Portfolio to Streamline Fluid Management from R&D to Bioprocess Manufacturing

    Portfolio now includes standard, configurable, and engineered-to-order peristaltic pumps, single-use assemblies, and systems for R&D through high-volume manufacturingCompany to attend INTERPHEX 2026 in New York City from April 21-23RADNOR, Pa., April 21, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to the life sciences and advanced technology industries, today announced the expansion of its Masterflex brand across its fluid handling portfolio, bringing together standard, configurable, and engineered-to-order peristaltic pumps, single-use assemblies, and systems.

    4/21/26 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Enhances U.S. Biomanufacturing Infrastructure with Expanded Stability and Microbial Testing Facility

    St. Louis site strengthens integrated support for biopharma manufacturingRADNOR, Pa., April 13, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced the expansion of its North American quality control capabilities with the addition of advanced microbial and stability testing at its St. Louis manufacturing site. The investment builds on Avantor's established global quality infrastructure, expanding and localizing capabilities to better sup

    4/13/26 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Report First Quarter 2026 Earnings on Wednesday, April 29, 2026

    RADNOR, Pa., April 3, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2026 financial results before the market opens on Wednesday, April 29, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Daylight Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A repl

    4/3/26 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Leadership Updates

    Live Leadership Updates

    View All

    Avantor® Appoints Simon Dingemans to its Board of Directors

    RADNOR, Pa., Dec. 18, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Simon Dingemans to its Board of Directors, effective January 2, 2026. Mr. Dingemans is an accomplished executive with extensive global leadership experience across healthcare, finance and strategic business transformation. He was previously the Chief Financial Officer of GlaxoSmithKline plc, a Partner at Goldman Sachs, and a Managing Dire

    12/18/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Sanjeev Mehra to its Board of Directors

    RADNOR, Pa., Dec. 4, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Sanjeev Mehra to its Board of Directors, effective immediately.   Mr. Mehra is Co-Founder and serves as Managing Partner of Periphas Capital LP, a private equity firm focused on investing in technology enabled businesses in services, consumer and industrial end markets. Prior to founding Periphas, Mr. Mehra spent over 30 years at Goldman,

    12/4/25 4:15:00 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Mary Blenn as Executive Vice President and Chief Operating Officer

    RADNOR, Pa., Nov. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced that Mary Blenn has been appointed to the newly created role of Executive Vice President and Chief Operating Officer, effective immediately. Ms. Blenn will report to President and CEO Emmanuel Ligner and will lead the Company's manufacturing and supply chain operations. She will be responsible for aligning Avantor's manufacturing and logistics network wit

    11/10/25 8:30:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Eck Steven W

    4 - Avantor, Inc. (0001722482) (Issuer)

    4/6/26 5:09:30 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Avantor Inc.

    4 - Avantor, Inc. (0001722482) (Issuer)

    3/11/26 5:10:29 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EVP, Chief Legal & Compliance Sokenu Claudius covered exercise/tax liability with 2,376 shares, decreasing direct ownership by 0.93% to 252,429 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    2/25/26 5:28:06 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    11/14/24 1:28:33 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/9/24 3:22:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/7/24 4:09:12 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lucier Gregory T bought $458,000 worth of shares (50,000 units at $9.16) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    2/23/26 8:53:53 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $940,000 worth of shares (100,000 units at $9.40) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    2/12/26 5:24:47 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Mehra Sanjeev K was granted 8,106 shares and bought $3,881,500 worth of shares (350,000 units at $11.09) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    12/9/25 5:11:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AVTR
    Financials

    Live finance-specific insights

    View All

    Avantor® to Report First Quarter 2026 Earnings on Wednesday, April 29, 2026

    RADNOR, Pa., April 3, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2026 financial results before the market opens on Wednesday, April 29, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Daylight Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A repl

    4/3/26 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports Fourth Quarter and Full Year 2025 Results

    Revival program underway, including relaunch of VWR brand, implementation of critical manufacturing and supply chain improvements, and upgrades to e-commerce channel Fourth Quarter 2025 Net sales of $1.66 billion, decrease of 1%; organic decrease of 4%Net income of $52 million; Adjusted EBITDA of $252 millionDiluted GAAP EPS of $0.08; adjusted EPS of $0.22Operating cash flow of $153 million; free cash flow of $117 millionFull Year 2025 Net sales of $6.55 billion, decrease of 3%; organic decline of 3%Net loss of $530 million; Adjusted EBITDA of $1,069 millionDiluted GAAP loss per share of $0.78; adjusted EPS of $0.90Operating cash flow of $624 million; free cash flow of $496 millionRADNOR, Pa

    2/11/26 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Report Fourth Quarter and Full Year 2025 Earnings on Wednesday, February 11, 2026

    RADNOR, Pa., Jan. 12, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Wednesday, February, 11, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Standard Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avanto

    1/12/26 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials